Floatz logo

Anti-Gd2-Car Engineered T Cells

Sarcoma

National Cancer Institute (NCI)Cell therapyPhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
73/ 100

Competitive context

110 Active assets in the Sarcoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
National Cancer Institute (NCI)
Phase 2BB
Ifosfamide
City of Hope Medical Center
Phase 3BB
Cyclophosphamide
Essen Biotech
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
Roswell Park Cancer Institute
Phase 2BB
Inno-206
City of Hope Medical Center
Phase 3BB

View all 50 →

Same molecule, other indications

Anti-Gd2-Car Engineered T Cells is also rated in:

neuroblastomaDormant
CCC
Indicative ·
53 / 100
View asset →
osteosarcomaDormant
CC
Indicative ·
44 / 100
View asset →
melanomaDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →